Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Nutr ; 131(9): 1473-1487, 2024 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-38221822

RESUMO

Vitamin D is a vital indicator of musculoskeletal health, as it plays an important role through the regulation of bone and mineral metabolism. This meta-analysis was performed to investigate the effects of vitamin D supplementation/fortification on bone turnover markers in women. All human randomised clinical trials reported changes in bone resorption markers (serum C-terminal telopeptide of type-I collagen (sCTX) and urinary type I collagen cross-linked N-telopeptide (uNTX)) or bone formation factors (osteocalcin (OC), bone alkaline phosphatase (BALP) and procollagen type-1 intact N-terminal propeptide (P1NP)) following vitamin D administration in women (aged ≥ 18 years) were considered. Mean differences (MD) and their respective 95 % CI were calculated based on fixed or random effects models according to the heterogeneity status. Subgroup analyses, meta-regression models, sensitivity analysis, risk of bias, publication bias and the quality of the included studies were also evaluated. We found that vitamin D supplementation had considerable effect on sCTX (MD: -0·038, n 22) and OC (MD: -0·610, n 24) with high heterogeneity and uNTX (MD: -8·188, n 6) without heterogeneity. Our results showed that age, sample size, dose, duration, baseline vitamin D level, study region and quality of studies might be sources of heterogeneity in this meta-analysis. Subgroup analysis also revealed significant reductions in P1NP level in dose less than 600 µg/d and larger study sample size (>100 participants). Moreover, no significant change was found in BALP level. Vitamin D supplementation/fortification significantly reduced bone resorption markers in women. However, results were inconsistent for bone formation markers.


Assuntos
Biomarcadores , Remodelação Óssea , Suplementos Nutricionais , Vitamina D , Humanos , Vitamina D/sangue , Vitamina D/administração & dosagem , Feminino , Biomarcadores/sangue , Remodelação Óssea/efeitos dos fármacos , Ensaios Clínicos Controlados Aleatórios como Assunto , Reabsorção Óssea/prevenção & controle , Colágeno Tipo I/sangue , Osso e Ossos/metabolismo , Osso e Ossos/efeitos dos fármacos , Osteocalcina/sangue , Fosfatase Alcalina/sangue , Peptídeos/sangue , Alimentos Fortificados
2.
Iran J Allergy Asthma Immunol ; 21(4): 478-483, 2022 Aug 12.
Artigo em Inglês | MEDLINE | ID: mdl-36243936

RESUMO

A novel coronavirus disease known as Coronavirus Disease 2019 (COVID-19) has spread quickly throughout the world, and it was declared a pandemic in March 2022. Chronic granulomatous disease (CGD) is a diverse group of genetic disorders characterized by recurrent bacterial and fungal infections, resulting in granulomas due to the inability of phagocytes to destroy microbes. Even though it is thought that impaired neutrophil activity is a protective mechanism against severe COVID-19-induced cytokine storms and hyper-inflammatory responses, patients with CGD have normal immunity to most viruses. Here, we present two CGD patients who were hospitalized due to severe COVID-19 infections, which suggests that COVID-19 might have a different pathogenesis than other viruses.


Assuntos
COVID-19 , Doença Granulomatosa Crônica , Doença Granulomatosa Crônica/complicações , Doença Granulomatosa Crônica/diagnóstico , Doença Granulomatosa Crônica/genética , Humanos , Fagócitos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...